Cargando…

PB1909: A STUDY ON TROUGH LEVELS OF GENERIC DASATINIB AND ITS CORRELATION WITH ADVERSE EVENTS AND EFFICACY.

Detalles Bibliográficos
Autores principales:	Nair, A., khadwal, A., jain, A., attri, S., pattnaik, S., Naseem, S., verma, N., jandial, A., lad, D., prakash, G., malhotra, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431685/ http://dx.doi.org/10.1097/01.HS9.0000850488.25615.d7

Ejemplares similares

PB2036: RISK AND PATTERN OF INFECTIONS IN NEWLY DIAGNOSED PATIENTS OF MULTIPLE MYELOMA VACCINATED UPFRONT AGAINST PNEUMOCOCCUS & INFLUENZA
por: VA, A., et al.
Publicado: (2022)

Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023)

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
por: Ranjit Kumar, C., et al.
Publicado: (2022)

PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION
por: László, Tamás, et al.
Publicado: (2023)

Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial)
por: Singh, Charanpreet, et al.
Publicado: (2022)

PB1739: ADVERSE EFFECTS OF ASPARAGINASE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
por: Chenbah, Wafa, et al.
Publicado: (2023)

Early bone loss in Indian patients undergoing allogeneic hematopoietic cell transplantation
por: Khaire, Niranjan S., et al.
Publicado: (2021)

PB1837: ANTIBIOTICS; A POSSIBLE ALTERNATE TREATMENT OPTION FOR MYELOID LEUKEMIA
por: Maham, Syeda, et al.
Publicado: (2023)

PB1712: LYOPHILIZATION BASED ISOLATION OF EXOSOMES FOR DELIVERY OF DRUGS AND PROTEIN
por: Rehman, Fawad Ur, et al.
Publicado: (2023)

PB2215: HYDROXYUREA-INDUCED CUTANEUS ADVERSE EVENTS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

PB1854: EARLY SEVERE ADVERSE EVENTS OF ACUTE MYELOID LEUKEMIA THERAPY DEPENDING ON THE INDUCTION THERAPY REGIMEN
por: Mikhailov, Evgeniy, et al.
Publicado: (2023)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

Role of fluoroquinolone prophylaxis in allogeneic hematopoietic cell transplantation in regions with a high prevalence of fluoroquinolone resistance
por: Nair, Ashwin, et al.
Publicado: (2023)

1909
por: Contreras, Gabriel 1959-
Publicado: (2009)

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Krishnan, A., et al.
Publicado: (2022)

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center
por: Chhabra, Prashant, et al.
Publicado: (2023)

PB2363: REPORTING LANGUAGE IN HAEMATOLOGICAL MALIGNANCIES
por: Watt, S., et al.
Publicado: (2022)

PB2303: REAL-WORLD TREATMENT PATTERNS AND ADVERSE EVENTS AMONG PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A RETROSPECTIVE DATABASE STUDY
por: Dharmani, Charles, et al.
Publicado: (2023)

PB2327: BONE MARROW STUDY IN THROMBOPENIA
por: López De Ugarriza, P., et al.
Publicado: (2022)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1754: TELOMERE LENGTH IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
por: Vakonaki, E., et al.
Publicado: (2022)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB1969: FUNCTIONAL CHARACTERIZATION OF SUSCEPTIBILITY LOCI TO MULTIPLE MYELOMA
por: Shokouhi, M., et al.
Publicado: (2022)

PB1918: MOLECULAR CHARACTERIZATION AND CLINICAL RELEVANCE OF ERYTHROPOIESIS IN MIELODYSPLASTIC SYNDROMES.
por: Villalba, A., et al.
Publicado: (2022)

PB1868: EXPERIENCE IN THE TREATMENT OF HAIRY CELL LEUKEMIA IN KAZAKHSTAN.
por: Kemelbekov, N., et al.
Publicado: (2022)

PB1916: SOMATIC MUTATIONS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME IN RUSSIAN PATIENTS
por: Kohno, A., et al.
Publicado: (2022)

PB2166: TET ENZYMES PROTECT AGAINST FATAL LYMPHOPROLIFERATION
por: Spoeck, S., et al.
Publicado: (2022)

PB2201: THYMUS DEVELOPMENT IN CONGENITAL HEART DISEASES
por: Bódi, I., et al.
Publicado: (2022)

PB1867: PURINE ANALOGS ON HAIRY CELL LEUKAEMIA TREATMENT
por: Gomes, G., et al.
Publicado: (2022)

PB2008: INCIDENCE OF DRUG-INDUCED MYELOSUPPRESSION AND ASSOCIATED ADVERSE EVENTS, QUALITY OF LIFE, AND MEDICAL RESOURCE USE IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
por: Nicolae, Maria Vutcovici, et al.
Publicado: (2023)

PB1931: HEMATOLOGICAL COMPLICATIONS OF COVID IMMUNIZATION-CASE SERIES
por: Aribandi, A., et al.
Publicado: (2022)

Short Research Communication Anti-Spike Antibody Response to COVISHIELD™ (SII-ChAdOx1 nCoV-19) Vaccine in Patients with B-Cell and Plasma Cell Malignancies and Hematopoietic Cell Transplantation Recipients
por: Chopra, Madhu, et al.
Publicado: (2022)

PB2350: SAFETY AND EFFICACY OF HYPODERMOCLYSIS IN PATIENTS WITH HEMATOLOGICAL CANCERS
por: Kodru, A., et al.
Publicado: (2022)

PB2049: MEXICAN REGISTRY OF MYELOPROLIFERATIVE NEOPLASMS. INITIAL REPORT
por: De La Peña Celaya, J. A., et al.
Publicado: (2022)

PB2204: THE ROLE OF HES6 IN NORMAL HUMAN HEMATOPOIESIS
por: De Vos, T., et al.
Publicado: (2022)

PB2053: PRIMARY ARTERIAL HYPERTENSION IN MYELOPROLIFERATIVE NEOPLASMS: A SYSTEMATIC REVIEW
por: Gaman, M.-A., et al.
Publicado: (2022)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB2274: A PROGNOSTIC MODEL TO PREDICT MORTALITY IN ICU DEPARTMENT OF HEMATOLOGY CLINIC
por: Luchinin, A., et al.
Publicado: (2022)

PB2344: RESILIENCE IN PATIENTS WITH LYMPHOID MALIGNANCIES: THE REPLY STUDY.
por: Dos Santos, G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lbcmb3jfpsgki9vaj766c7rpao